Holen Sie sich die Stockscreener-App
8.59
2.75%
0.23
Handel nachbörslich:
8.59
Schlusskurs vom Vortag:
$8.36
Offen:
$8.39
24-Stunden-Volumen:
710.23K
Relative Volume:
0.61
Marktkapitalisierung:
$1.06B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-2.7799
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
-0.35%
1M Leistung:
-6.83%
6M Leistung:
-43.23%
1J Leistung:
-41.37%
1-Tages-Spanne:
$8.30
$8.81
1-Wochen-Bereich:
$7.91
$8.81
52-Wochen-Spanne:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
8.59 | 1.06B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
(RCUS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
GAMMA Investing LLC Buys 15,466 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: promising cancer therapy stock faces pivotal year - Investing.com
Arcus Biosciences Sees Unusually High Options Volume (NYSE:RCUS) - Defense World
Arcus Biosciences Holds Annual Stockholders Meeting - TipRanks
Arcus Biosciences Inc Inc. (RCUS) Price Performance: A Technical Analysis Perspective - investchronicle.com
Positive Signs As Multiple Insiders Buy Arcus Biosciences Stock - simplywall.st
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,872 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Comments on RCUS FY2026 Earnings - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
When the Price of (RCUS) Talks, People Listen - news.stocktradersdaily.com
Nuveen Asset Management LLC Has $1.96 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Bank of America Corp DE - Defense World
Arcus Biosciences (RCUS) Unveils Promising Data for Cancer Treat - GuruFocus
Transcript : Arcus Biosciences, Inc.Special Call - MarketScreener
Arcus Biosciences Presents Promising Phase 1/1b Trial Data - TipRanks
Two Sigma Investments LP Purchases 11,027 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences (RCUS) Unveils Promising Data for Cancer Treatment | RCUS Stock News - GuruFocus
Arcus Says Initial Data From The Arc-20 Study Of Casdatifan Plus Cabozantinib Showed Nearly Half Of Patients With Metastatic Kidney Cancer Had A Confirmed Response - marketscreener.com
ProShare Advisors LLC Increases Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences (NYSE:RCUS) Shares Down 8.6% – Here’s What Happened - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Arcus Biosciences’ SWOT analysis: stock’s potential in cancer therapy market By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Purchases 9,016 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Deutsche Bank AG Boosts Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: stock’s potential in cancer therapy market - Investing.com
Lazard Asset Management LLC Has $93,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS) - The Globe and Mail
Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy - ACS Publications
Recent Investment Analysts’ Ratings Changes for Arcus Biosciences (RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Northern Trust Corp - Defense World
Arcus Biosciences Stock May Be The Next To Fail (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Slashed This Year's Revenue Estimates By 17% - simplywall.st
Trading (RCUS) With Integrated Risk Controls - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Sells 6,265 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Cuts Arcus Biosciences (NYSE:RCUS) Price Target to $22.00 - Defense World
First Trust Advisors LP Has $264,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Has Weak Forecast for RCUS FY2025 Earnings - Defense World
HC Wainwright Predicts Weaker Earnings for Arcus Biosciences - Defense World
Arcus Biosciences (RCUS): Morgan Stanley Lowers Price Target | R - GuruFocus
Wedbush Decreases Earnings Estimates for Arcus Biosciences - Defense World
Raymond James Financial Inc. Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating - marketscreener.com
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates - MSN
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) - GuruFocus
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) | RCUS Stock News - GuruFocus
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) to $26 | RCUS Stock News - GuruFocus
Arcus Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wel - GuruFocus
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arcus Biosciences Inc-Aktie (RCUS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROSEN TERRY J | Chief Executive Officer |
Feb 27 '25 |
Buy |
10.18 |
19,800 |
201,465 |
2,554,160 |
| GILEAD SCIENCES, INC. | 10% Owner |
Feb 18 '25 |
Buy |
11.00 |
1,363,636 |
14,999,996 |
31,424,760 |
| Goeltz II Robert C. | Chief Financial Officer |
Dec 31 '24 |
Sale |
15.00 |
3,594 |
53,910 |
60,138 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):